Modified GRF 1-29

CJC-1295 no DAC, also known as Modified GRF 1-29, is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids with four strategic amino acid substitutions designed to enhance stability and bioactivity. Unlike CJC-1295 with DAC, this variant lacks the drug affinity complex, resulting in a shorter half-life of 30 minutes to 2 hours that promotes pulsatile growth hormone secretion mimicking natural physiological patterns. Research demonstrates it can increase growth hormone levels by 2- to 10-fold and IGF-1 concentrations by 1.5- to 3-fold in clinical trials. The peptide has been studied for potential applications in age-related GH decline, body composition optimization, and metabolic health. CJC-1295 no DAC is not FDA-approved for human use and is classified as a prohibited substance by WADA for athletic competition. It is available through compounding pharmacies for research purposes, though regulatory status remains uncertain following recent FDA actions on peptide compounding.

Mechanism of Action

CJC-1295 no DAC functions as a GHRH receptor agonist, binding to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary gland ^[1]. This activation triggers G-protein coupled receptor pathways, increasing cyclic AMP and protein kinase A activity, ultimately stimulating pulsatile growth hormone release that mirrors natural physiological patterns ^[2].

Growth Hormone and IGF-1 Enhancement

• Sustained GH elevation: Clinical trials demonstrate dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold lasting 6 days or more following a single injection ^[3]
• IGF-1 production: Corresponding increases in IGF-1 levels of 1.5- to 3-fold for 9-11 days, with preserved natural pulsatility patterns ^[3][4]
• Enhanced pulsatile secretion: Maintains physiological GH pulse patterns while increasing basal trough levels by 7.5-fold and mean GH by 46% ^[4]
• Age-related decline reversal: Successfully restores GH and IGF-1 levels in elderly men to match those of young adults ^[5]

Body Composition and Metabolic Effects

• Lean body mass preservation: Animal studies show normalized body composition with maintained fat-free mass comparable to healthy controls ^[2]
• Visceral fat reduction: Research in HIV-associated lipodystrophy demonstrates trunk fat decreases and improved body composition ^[6]
• Insulin sensitivity preservation: Short-term treatment augments GH secretion without impairing peripheral insulin-stimulated glucose uptake ^[7]
• Metabolic function: Maintains normal metabolic parameters including glucose homeostasis in clinical studies ^[5][6]

Cellular and Regenerative Effects

• Somatotroph proliferation: Stimulates increased pituitary RNA and GH mRNA, suggesting proliferation of growth hormone-producing cells ^[2]
• Tissue regeneration potential: GHRH analogs demonstrate effects on wound healing, muscle repair, and cellular regeneration in preclinical models ^[8]
• Neuroprotective properties: Related GHRH agonists show sleep-enhancing effects and potential amyloid-beta reduction in Alzheimer's models ^[9]

Structural Stability Advantages

• Enhanced bioactivity: Four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) prevent enzymatic degradation and oxidation ^[1]
• DPP-IV resistance: Modifications protect against dipeptidyl peptidase-IV cleavage, extending functional duration ^[1]
• Improved potency: Demonstrates 4-fold increase in GH area under the curve compared to natural GHRH(1-29) ^[10]

Clinical Safety Profile

Well-tolerated in clinical trials: Subcutaneous administration has been demonstrated as safe and relatively well-tolerated in healthy adults, particularly at doses of 30-60 micrograms per kilogram ^[3]. No serious adverse reactions were reported in major clinical studies examining both single-dose and multiple-dose regimens lasting 28-49 days ^[3][4].

Age-related studies: Short-term subcutaneous administration in elderly men showed no adverse effects on fasting glucose, urinary C-peptide, blood pressure, or standard chemistry and hematology profiles ^[5]. Treatment successfully reversed age-related GH decline without safety concerns in controlled trials ^[5].

Common Side Effects

• Injection site reactions: Redness, swelling, or discomfort at injection sites are the most commonly reported effects ^[1]
• Mild transient symptoms: Skin flushing, warmth, dizziness, and transient hypotension may occur following injection, typically dissipating with repeated administration ^[1]
• Gastrointestinal effects: Nausea, stomach upset, abdominal pain, and diarrhea have been reported in some users ^[1]
• Neurological symptoms: Headache, sleepiness, or feelings of tiredness may occur, as GH can increase desire for sleep ^[1]
• Dose-dependent effects: Excessive dosages may lead to tingling or numbness in extremities and water retention, indicating need for dose reduction ^[1]

Serious Safety Considerations

Long-term injection site complications: Subcutaneous nodule formation and lipoatrophy at injection sites have been documented in extended-use studies, potentially contributing to treatment noncompliance ^[11]. Cancer risk: Should not be used by individuals with history of cancer, as growth hormone stimulation may theoretically promote cancerous cell growth ^[1]. Cardiovascular concerns: People with heart conditions or high blood pressure should avoid use; FDA cited cardiovascular safety concerns including tachycardia and arrhythmias in recent regulatory actions ^[12].

Regulatory Status

Not FDA-approved: CJC-1295 no DAC has not been approved by the FDA for human therapeutic use, and all current applications are off-label ^[12]. Recent regulatory changes: In August 2024, the FDA initially banned compounding of CJC-1295, but in September 2024, removed it from the Category 2 list, leaving regulatory status in limbo pending final determination ^[12]. WADA prohibition: Classified as a prohibited substance under Section S2 of the World Anti-Doping Agency list as a growth hormone releasing factor .

Research Gaps and Limitations

Limited human data: Most clinical trials involved small sample sizes and short durations (weeks to months), with limited large-scale, long-term safety studies specifically examining Modified GRF 1-29 ^[3][4][5]. Metabolic monitoring needed: While short-term studies show preserved insulin sensitivity, long-term metabolic effects require further investigation ^[7]. Detection challenges: The peptide's low abundance and short half-life make anti-doping detection difficult, though LC-MS/MS methods have been developed . Optimal dosing unclear: Clinical trials used varying protocols, and consensus on optimal therapeutic dosing for specific indications has not been established ^[3][5][6].